Mölnlycke successfully prices a EUR 500M bond maturing 2034
Gothenburg, 4 June 2024: Mölnlycke, a world-leading MedTech company, has successfully raised EUR 500M in the corporate bond market under its Euro Medium Term Note (EMTN) programme. The bond has a 10-year tenor with an annual fixed coupon of 4.25%, corresponding to mid swaps of +1.55 percentage points.
The bond was more than five times oversubscribed with an orderbook of over EUR 2,700M at its peak. There was strong and widespread demand from leading investors in Germany, Austria and Switzerland 32%, UK & Ireland 28%, Nordics 18%, France 12% and Other 10%. Asset Managers represented 87% of investors, followed by Insurance and Pension Funds with 9% and Banks with 4%.
The proceeds will be used to finance a Tender Offer of Mölnlycke’s outstanding EUR 500M notes maturing in 2025 as well as for general corporate purposes. The bond further extends the duration of Mölnlycke’s well-spread debt maturity profile.
The bond will be listed on the Euro MTF market of the Luxembourg Stock Exchange.
BNP Paribas, ING, JP Morgan and SEB acted as joint bookrunners for the transaction.
Latest press releases
Go to Media room-
Mölnlycke launches Biogel® Radiation Protection® gloves to tackle low adoption of hand protection in radiation-guided surgical procedures
Clinicians’ hands can receive up to 1,000 times more radiation than other parts of the body during image-guided procedures1; yet, radiation-attenuating gloves are used in only 10% of applicable cases2, putting healthcare professionals at risk of the damaging effects of radiation.
-
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
-
Mölnlycke Recognized with Cardinal Health 2026 Rising Star Award
Mölnlycke Health Care has been honored with the Cardinal Health 2026 Rising Star Award, recognizing outstanding performance as a new member of the Cardinal Health Performance Plus Program.The award was presented during Cardinal Health's National Sales Meeting, held the week of August 9th, and reflects the strength of the partnership between the two organizations across Advanced Wound Care, Patient Positioning, and Antiseptics.
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
-
Mölnlycke Health Care accelerates U.S. growth journey with three wound care product launches
Peachtree Corners, GA. July 7, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.
-
Mölnlycke Health Care announces Andreas Johansson as Interim Chief Financial Officer
Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect.
-
Mölnlycke advocates a holistic approach to healthcare sustainability
New white paper calls for integration of environmental, human and economic metrics in sustainability assessments of medical technologies.
-
Mölnlycke Health Care expands investment in Tamer Mölnlycke Care joint venture
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.
-
Mölnlycke Health Care agrees to acquire leading wound cleansing manufacturer to consolidate its position as global leader in wound care
Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.